CytoReason vs TrialJectory
CytoReason vs TrialJectory, compared side by side on 19 data points: what each one does, how big it is, what it has raised, the tech running each site, and what users report. We score both out of 100 on traction, team and visibility: CytoReason is on 68/100 and TrialJectory on 58/100.
Where each one leads
CytoReason
- our overall score: 68/100 against 58/100
- headcount: 116 against 17
- headcount growth: +13.7% against -33.1%
- funding raised: $128M against $39.7M
- LinkedIn following: 12,830 against 4,387
TrialJectory
- agent readiness: 32/100 against 21/100
At a glance
| Measure | CytoReason | TrialJectory |
|---|---|---|
| What it is | Develops a computational model of the human body for drug discovery and development. | AI-powered platform connecting cancer patients to advanced treatments and clinical trials. |
| Category | Healthcare, Drug Discovery, Clinical Development, Biomarkers | Healthcare, Clinical Trials, Cancer, HealthTech |
| Sells toBusiness model | B2B | B2B |
| Offering | Software | Software |
| Founded | 2016 | 2017 |
| Headquarters | Tel Aviv, Israel | New York, United States |
| Status | Active | Active |
Size, funding and growth
| Measure | CytoReason | TrialJectory |
|---|---|---|
| Employees | 116 | 17 |
| Headcount growthLast 12 months | +13.7% | -33.1% |
| Total funding | $128M | $39.7M |
| Latest round | Series B | Series A |
| LinkedIn followers | 12,830 | 4,387 |
StartupHub scores
Our own 0-100 ratings. They measure company strength and site quality, not which product suits you.
| Measure | CytoReason | TrialJectory |
|---|---|---|
| StartupHub scoreOur 0-100 rating | 68/100 | 58/100 |
| Traction | 60/100 | 51/100 |
| Team | 70/100 | 70/100 |
| Search visibility | 30/100 | 36/100 |
| Quality | 78/100 | 62/100 |
| Agent readinessHow well an AI agent can read and act on the site | F (21/100) | F (32/100) |
| Domain ratingLink authority, 0-100 | 40/100 | 39/100 |
Technology
Detected on each public site, so it reflects the marketing stack as well as the product.
| Measure | CytoReason | TrialJectory |
|---|---|---|
| Hosting | Not detected | AWS |
| CDN | Not detected | CloudFront |
| Frameworks | Not detected | Next.js |
| Analytics | Segment | Not detected |
CytoReason vs TrialJectory: common questions
Which is better, CytoReason or TrialJectory?
On our 0-100 score CytoReason rates higher (68/100 against 58/100). The score weights traction, team, visibility and profile completeness, so it reflects company strength rather than which product suits you. We compare the two on 19 data points above: read the rows that match what you are buying for.
How do CytoReason and TrialJectory compare on the numbers?
CytoReason leads on our overall score (68/100 against 58/100), headcount (116 against 17), headcount growth (+13.7% against -33.1%), funding raised ($128M against $39.7M), LinkedIn following (12,830 against 4,387). TrialJectory leads on agent readiness (32/100 against 21/100).
Read the full CytoReason review and pricing or the TrialJectory review and pricing. You can also browse other CytoReason alternatives we track.